Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 270

1.

The Lake Wobegon Effect: Why Most Patients Are at Below-Average Risk.

Vickers AJ, Kent DM.

Ann Intern Med. 2015 Apr 14. doi: 10.7326/M14-2767. [Epub ahead of print] No abstract available.

PMID:
25867499
2.

Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study.

Bryant RJ, Sjoberg DD, Vickers AJ, Robinson MC, Kumar R, Marsden L, Davis M, Scardino PT, Donovan J, Neal DE, Lilja H, Hamdy FC.

J Natl Cancer Inst. 2015 Apr 11;107(7). pii: djv095. doi: 10.1093/jnci/djv095. Print 2015 Jul.

3.

Impact of stage migration and practice changes on high risk prostate cancer: results from patients treated with radical prostatectomy over the last two decades.

Fossati N, Passoni NM, Moschini M, Gandaglia G, Larcher A, Freschi M, Guazzoni G, Sjoberg DD, Vickers AJ, Montorsi F, Briganti A.

BJU Int. 2015 Mar 17. doi: 10.1111/bju.13125. [Epub ahead of print]

PMID:
25787671
4.

Nonlinear modeling was applied thoughtfully for risk prediction: the Prostate Biopsy Collaborative Group.

Nieboer D, Vergouwe Y, Roobol MJ, Ankerst DP, Kattan MW, Vickers AJ, Steyerberg EW; Prostate Biopsy Collaborative Group.

J Clin Epidemiol. 2015 Apr;68(4):426-34. doi: 10.1016/j.jclinepi.2014.11.022. Epub 2014 Nov 29.

PMID:
25777297
5.

Informed decision making about prostate cancer screening.

Vickers AJ.

Ann Intern Med. 2015 Mar 17;162(6):457-8. doi: 10.7326/L15-5063-2. No abstract available.

PMID:
25775325
6.

Are we ready to predict late effects? A systematic review of clinically useful prediction models.

Salz T, Baxi SS, Raghunathan N, Onstad EE, Freedman AN, Moskowitz CS, Dalton SO, Goodman KA, Johansen C, Matasar MJ, de Nully Brown P, Oeffinger KC, Vickers AJ.

Eur J Cancer. 2015 Apr;51(6):758-766. doi: 10.1016/j.ejca.2015.02.002. Epub 2015 Feb 27. Review.

PMID:
25736818
7.

Four flawed arguments against prostate-specific antigen screening (and 1 good one).

Vickers AJ.

Urology. 2015 Mar;85(3):491-4. doi: 10.1016/j.urology.2014.11.003.

PMID:
25733258
8.

Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature.

Kluth LA, Black PC, Bochner BH, Catto J, Lerner SP, Stenzl A, Sylvester R, Vickers AJ, Xylinas E, Shariat SF.

Eur Urol. 2015 Feb 20. pii: S0302-2838(15)00075-5. doi: 10.1016/j.eururo.2015.01.032. [Epub ahead of print] Review.

PMID:
25709027
9.

Preoperative predictive model of recovery of urinary continence after radical prostatectomy.

Matsushita K, Kent MT, Vickers AJ, von Bodman C, Bernstein M, Touijer KA, Coleman JA, Laudone VT, Scardino PT, Eastham JA, Akin O, Sandhu JS.

BJU Int. 2015 Feb 13. doi: 10.1111/bju.13087. [Epub ahead of print]

PMID:
25682782
10.

Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.

Stattin P, Vickers AJ, Sjoberg DD, Johansson R, Granfors T, Johansson M, Pettersson K, Scardino PT, Hallmans G, Lilja H.

Eur Urol. 2015 Feb 11. pii: S0302-2838(15)00024-X. doi: 10.1016/j.eururo.2015.01.009. [Epub ahead of print]

11.

The Next Generation of Clinical Decision Making Tools: Development of a Real-Time Prediction Tool for Outcome of Prostate Biopsy in Response to a Continuously Evolving Prostate Cancer Landscape.

Strobl AN, Thompson IM, Vickers AJ, Ankerst DP.

J Urol. 2015 Jan 28. pii: S0022-5347(15)00184-6. doi: 10.1016/j.juro.2015.01.092. [Epub ahead of print]

PMID:
25636656
12.

Reply: To PMID 25623680.

Vickers AJ.

Urology. 2015 Feb;85(2):342. doi: 10.1016/j.urology.2014.08.052. No abstract available.

PMID:
25623682
13.

Decision analysis of dutasteride use for patients with negative prostate biopsy.

Vickers AJ, Sjoberg DD.

Urology. 2015 Feb;85(2):337-41. doi: 10.1016/j.urology.2014.08.048.

PMID:
25623680
14.

Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration.

Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, Vickers AJ, Ransohoff DF, Collins GS.

Ann Intern Med. 2015 Jan 6;162(1):W1-73. doi: 10.7326/M14-0698.

PMID:
25560730
15.

A Systematic Literature Review of Life Expectancy Prediction Tools for Patients with Localized Prostate Cancer.

Kent M, Vickers AJ.

J Urol. 2014 Nov 15. pii: S0022-5347(14)04929-5. doi: 10.1016/j.juro.2014.11.082. [Epub ahead of print]

PMID:
25463998
16.

Response from the author.

Vickers AJ.

Clin Trials. 2014 Dec;11(6):628. doi: 10.1177/1740774514553486. No abstract available.

PMID:
25389228
17.

Markers for the early detection of prostate cancer: some principles for statistical reporting and interpretation.

Vickers AJ.

J Clin Oncol. 2014 Dec 20;32(36):4033-4. doi: 10.1200/JCO.2014.58.5547. Epub 2014 Nov 3. No abstract available.

PMID:
25366689
18.

Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.

Brockman JA, Alanee S, Vickers AJ, Scardino PT, Wood DP, Kibel AS, Lin DW, Bianco Jr FJ, Rabah DM, Klein EA, Ciezki JP, Gao T, Kattan MW, Stephenson AJ.

Eur Urol. 2014 Oct 6. pii: S0302-2838(14)00956-7. doi: 10.1016/j.eururo.2014.09.019. [Epub ahead of print]

PMID:
25301759
19.

Clinical trials in crisis: Four simple methodologic fixes.

Vickers AJ.

Clin Trials. 2014 Dec;11(6):615-21. doi: 10.1177/1740774514553681. Epub 2014 Oct 1.

PMID:
25278228
20.

A simple schema for informed decision making about prostate cancer screening.

Vickers AJ, Edwards K, Cooperberg MR, Mushlin AI.

Ann Intern Med. 2014 Sep 16;161(6):441-2. doi: 10.7326/M14-0151. No abstract available.

PMID:
25222389
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk